We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cabaletta Bio Inc | NASDAQ:CABA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.58 | -5.26% | 10.44 | 10.15 | 11.35 | 11.31 | 10.34 | 10.78 | 763,495 | 01:00:00 |
As filed with the Securities and Exchange Commission on August 10, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
CABALETTA BIO, INC.
(Exact name of registrant as specified in its charter)
Delaware | 82-1685768 | |
(State or other jurisdiction of incorporation) |
(I.R.S. Employer Identification No.) | |
2929 Arch Street, Suite 600 Philadelphia, PA |
19104 | |
(Address of principal executive offices) | (Zip Code) |
Cabaletta Bio, Inc.
2019 Stock Option and Incentive Plan
(Full title of the plan)
Steven Nichtberger
President and Chief Executive Officer
Cabaletta Bio, Inc.
2929 Arch Street, Suite 600
Philadelphia, PA 19104
(267) 759-3100
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Emerging growth company | ☒ | |||
Smaller reporting company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
STATEMENT OF INCORPORATION BY REFERENCE
This Registration Statement on Form S-8 registers 3,000,000 additional shares of the Registrants common stock, $0.00001 par value per share (Common Stock), to be issued under the Registrants 2019 Stock Option and Incentive Plan, as amended (the 2019 Plan). The additional shares represent an increase in the number of shares of Common Stock reserved for issuance under the 2019 Plan, which increase was previously approved by the Board and subsequently approved by the Registrants stockholders on June 1, 2023 at the Registrants 2023 Annual Meeting of Stockholders.
The additional shares described above are of the same class as other securities relating to the 2019 Plan for which the Registrants registration statement on Form S-8 (File No. 333-234367), filed with the U.S. Securities and Exchange Commission (the Commission) on October 29, 2019, is effective. The information contained in the Registrants registration statement on Form S-8 (Registration No. 333-234367), filed with the Commission on October 29, 2019, is hereby incorporated by reference pursuant to General Instruction E to Form S-8.
Part II
Information Required in the Registration Statement
Item 8. | Exhibits |
Refer to the Exhibit Index on the next page for a list of exhibits filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
* | Filed herewith. |
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Philadelphia, Commonwealth of Pennsylvania, on this 10th day of August, 2023.
CABALETTA BIO, INC. | ||
By: | /s/ Steven Nichtberger | |
Steven Nichtberger, M.D. | ||
President and Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Steven Nichtberger and Anup Marda as such persons true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such persons name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.
Name |
Title |
Date | ||
/s/ Steven Nichtberger Steven Nichtberger, M.D. |
President, Chief Executive Officer and Director (Principal Executive Officer) |
August 10, 2023 | ||
/s/ Anup Marda Anup Marda |
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
August 10, 2023 | ||
/s/ Catherine Bollard Catherine Bollard, M.D. |
Director | August 10, 2023 | ||
/s/ Scott C. Brun Scott C. Brun, M.D. |
Director | August 10, 2023 | ||
/s/ Richard Henriques Richard Henriques |
Director | August 10, 2023 | ||
/s/ Mark Simon Mark Simon |
Director | August 10, 2023 | ||
/s/ Shawn Tomasello |
Director | August 10, 2023 | ||
Shawn Tomasello |
Exhibit 5.1
August 10, 2023
Cabaletta Bio, Inc.
2929 Arch Street, Suite 600
Philadelphia, PA 19104
Re: | Securities Being Registered under Registration Statement on Form S-8 |
We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the Registration Statement) pursuant to the Securities Act of 1933, as amended (the Securities Act), on or about the date hereof relating to an aggregate of 3,000,000 shares (the Shares) of Common Stock, $0.00001 par value per share (Common Stock), of Cabaletta Bio, Inc., a Delaware corporation (the Company), that may be issued pursuant to the Companys 2019 Stock Option and Incentive Plan, as amended (the Plan).
We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.
The opinion set forth below is limited to the Delaware General Corporation Law.
For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.
Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.
This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 Business Lawyer 815 (Summer 2019).
We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.
Very truly yours, |
/s/ Goodwin Procter LLP GOODWIN PROCTER LLP |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan of our report dated March 16, 2023, with respect to the financial statements of Cabaletta Bio, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP |
Philadelphia, Pennsylvania |
August 10, 2023 |
Exhibit 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
Cabaletta Bio, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type | Security Class Title |
Fee Calculation Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Share |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee | |||||||
Equity | 2019 Stock Option and Incentive Plan, as amended, Common Stock, $0.00001 par value per share | Other(2) | 3,000,000(3) | $12.15(2) | $36,442,500.00 | $0.00011020 | $4,015.97 | |||||||
Total Offering Amounts | | |||||||||||||
Total Fees Previously Paid | | |||||||||||||
Total Fee Offsets | | |||||||||||||
Net Fee Due | $4,015.97 |
(1) | In accordance with Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this registration statement on Form S-8 shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock, $0.00001 par value per share (Common Stock). |
(2) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The price per share and aggregate offering price are calculated on the basis of $12.15, the average of the high and low price of the Registrants Common Stock as reported on the Nasdaq Global Select Market on August 4, 2023. |
(3) | Represents an additional 3,000,000 shares of Common Stock issuable under the 2019 Stock Option and Incentive Plan, as amended (2019 Plan). These 3,000,000 shares of Common Stock represent an increase in the number of shares of common stock reserved for issuance under the 2019 Plan, which increase was approved by the Registrants stockholders on June 1, 2023 at the Registrants 2023 Annual Meeting of Stockholders. Shares available for issuance under the 2019 Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on October 29, 2019 (Registration No. 333-234367), March 30, 2020 (Registration No. 333-237484), March 16, 2021 (Registration No. 333-254342), March 17, 2022 (Registration No. 333-263637) and March 16, 2023 (Registration No. 333-270595). |
1 Year Cabaletta Bio Chart |
1 Month Cabaletta Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions